セッション詳細
[O2]Oral Presentations 2
2026年3月3日(火) 8:30 〜 9:30
神戸ポートピアホテル(南館1F「大輪田」)
【研究開発 I】
【R&D I】
【R&D I】
[O2-01]Development of a Therapeutic Live-Attenuated HSV-2 Vaccine
*YASUSHI KAWAGUCHI1 (1. The UTOPIA Center, The University of Tokyo (Japan))
[O2-02]Development of a Live Attenuated Tetravalent Dengue Vaccine (KD-382)
*Motoharu Abe1 (1. DEJIMA Infectious Disease Research Alliance, Vaccine Research and Development Center, Nagasaki University (Japan))
[O2-03]T細胞応答を基盤としたデング熱・ジカ熱の交叉防御型次世代ワクチン技術
Next-Generation Cross-Protective Vaccine Technology Against Dengue and Zika Based on T Cell–Mediated Immune Responses
*Meng Ling Moi1,2 (1. Graduate School of Medicine, the University of Tokyo (Japan), 2. The UTOPIA Center, The University of Tokyo (Japan))
[O2-04E]インフルエンザ/新型コロナウイルス感染症混合ワクチンの研究開発とその必要性について
Development of the influenza/COVID-19 combined vaccine and its importance
*Marumi Ohno1,2,3, Chimuka Handabile1,2, Richard Obeng-Kyeremeh1, Minori Haruta1, Toshiki Sekiya1,2,4, Tomomi Kawakita1, Naoki Nomura1, Masashi Shingai1,2, Hiroshi Kida1,2 (1. International Institute for Zoonosis Control, Hokkaido University (Japan), 2. Institute for Vaccine Research and Development (IVReD), Hokkaido University (Japan), 3. One Health Research Center, Hokkaido Univeristy (Japan), 4. Peter Doherty Institute, Melbourne University (Australia))
[O2-05]SFTSに対する弱毒生ワクチンの開発
Development of a live attenuated vaccine against SFTS
*Jiro Yasuda1 (1. VRDC, Nagasaki University (Japan))
[O2-06]Development of Effective and Safe Vaccines for SARS-CoV-2, Ebola virus, and influenza viruses based on single cycle replicating viruses
*Yoshihiro Kawaoka1 (1. UTOPIA (Japan))